In summary, our study suggests that the clinical usefulness of GRPR-targeted radiopharmaceuticals in the maintenance or metastatic treatment of uterine cervix cancer might be beneficial based on the high frequency of GRPR overexpression. The gene discussed is GRPR; the disease is cervical cancer.